News

Horizon Europe Cluster 2 Work Programme 2021-2022 published

Published on | 4 years ago

Programmes Culture and society

The 2021-2022 Work Programme of Cluster 2 - Culture, Creativity and Inclusive Society has been adopted by the European Commission and published. The Work Programme can be found on the Funding and Tenders Portal or on the Cluster 2 webpage on our website.

The 2021 calls of Cluster 2 will open on 22 June 2021 and close on 7 October 2021.

On 1 July, The European Commission will organize an online info day for Cluster 2 and the call topics of the 2021-2022 Work Programme will be presented. Additionally a brokerage event will be organized on 2 July. More information on these events can be found here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1773 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.